real-world-benefit-shown-in-T2D-treatment
Real-world evidence study shows type 2 diabetes treatment reduced risk of cardiovascular events and hospitalization for heart failure
Search
Advance study vaccinating increased milk production
[New ADVANCE study shows vaccinating with Bovela® results in increased milk production
discontinuation-bi-1467335-diabetic-retinopathy
The discontinuation of the development of BI 1467335 in diabetic retinopathy has been announced
Boehringer Ingelheim strong growth pipeline acceleration 2023
Boehringer Ingelheim reports strong growth in 2023 and accelerates late-stage pipeline
REACH / GHS / Material safety data sheets
We are continuously working on these topics with the aim to be in compliance with requirements deriving from these legislations.
EU approved Jardiance for type 2 diabetes in children
Jardiance® (empagliflozin) receives approval in the EU for the treatment of type 2 diabetes in children aged 10 years and above
1990-2022: Value through Innovation
The Boehringer Ingelheim history from 1990 to 2023, with milestones
additional-investment-in-Lyon-Jonage
Boehringer Ingelheim to expand veterinary vaccine capacity for emerging and transboundary diseases in France
Boehringer expands production site in Greece
Boehringer expands production site in Greece for new medicine
Brightline-1 trial launch in rare sarcoma
Mehdi Lahmar discusses “Brightline-1”, and our commitment to patients with Dedifferentiated Liposarcoma (DDLPS).
AI&Data Science Fellowship Tuebingen
AI&Data Science Fellowship Tuebingen
A guide to hidradenitis suppurativa (HS)
Hidradenitis suppurativa (HS) is a long-term, inflammatory, recurrent, skin condition that causes painful inflamed nodules, or abscesses on the skin
Over 100 billion birds vaccinated with VAXXITEK
Boehringer Ingelheim celebrates that over 100 billion birds have been vaccinated with VAXXITEK® HVT + IBD in October 2018.
Big molecules - Huge potential | Bioxcellence | Boehringer Ingelheim
Explore the potential of big molecules with BioXcellence, offering advanced biopharmaceutical production services to unlock new possibilities in healthcare.
Phase II trials for patients with bronchiectasis
Bronchiectasis is a chronically progressive pulmonary disease. Boehringer Ingelheim investigates a potential new treatment option in two Phase II trials.
Boehringer Ingelheim announces 2018 BVDzero Case Awards
Boehringer Ingelheim announces 2018 BVDzero Case Awards Boehringer Ingelheim will provide a total prize of €15,000 for the top 10 clinical cases entered Applications can be submitted on www.bvdzero.com
Stem cell therapy for tendon and ligament injuries in horses
A tendon or ligament injury can be devastating for horse owners, riders and trainers. Our new stem cell product improves the quality of healing.
We are Global Top Employer 2024
Global Top Employer certification reflects our impactful people development with high scores in development and steering practices as well as benefits on employee wellbeing.
SENVELGO Best New Product Companion Animals award
SENVELGO won the 2023 Animal Health Best New Product for Companion Animals award
Biopharmaceuticals: large molecules, enormous potential
Researching, developing and manufacturing biopharmaceuticals is a highly complex and lengthy process, but it has enormous potential.
Connect the Docs
Experts discuss interconnectivitiy of heart failure, diabetes, and kidney disease and the importance of early diagnosis.
Boehringer Ingelheim leader in hatchery vaccination
Boehringer Ingelheim is a leader in hatchery vaccination with vector vaccines.
Accelerating new cancer medicines in partnership with CBmed
Boehringer Ingelheim and CBmed join forces to translate novel cancer therapy approaches faster into new medicines for patients
Vaccine bluetongue virus serotype 3 sheep cattle
BULTAVO 3™ is a new vaccine that protects cattle and sheep against bluetongue virus serotype 3 (BTV-3). BULTAVO 3™ is the first BTV-3 vaccine that prevents clinical signs and mortality.
Bluetongue disease
The bluetongue virus is a viral disease that affects ruminants' health. It doesn't affect humans, but it is a threat to animals.